CIK and issuer name are linked to the captured SEC filing sequence.
ISSUER DOSSIER · CIK 0001643918
Biodexa Pharmaceuticals Plc (BDRX)
Business context
Official filing overview: we provide any assurance as to the reliability of, any information other than the information in this prospectus.
First captured2025-12-08
Latest filingF-1/A · 2026-07-30
Registration path0 initial filings · 3 amendments
ISSUER CHANGE LEDGER
Newly detected public-record events
Events first captured by this monitoring workflow for this CIK. Open the source and the filing brief before making any legal, diligence or transaction conclusion.
- F-1/ABiodexa Pharmaceuticals Plc (BDRX)Official source →
- F-1/ABiodexa Pharmaceuticals Plc (BDRX)Official source →
- F-1/ABiodexa Pharmaceuticals Plc (BDRX)Official source →
SHELL DILIGENCE CHAIN · PUBLIC-RECORD VIEW
Evidence chain for this issuer
Built from 3 captured SEC filing nodes, from 2025-12-08 through 2026-07-30. It shows what has been observed in the record and what still needs independent verification.
- Identity anchorCIK 0001643918 · issuer name carried from the SEC filing history
- Registration entryNo initial S-1 / F-1 is in the captured record
- Amendment trail3 amendments captured
- Effectiveness / prospectusNo EFFECT or 424B is in the captured record
- Ongoing record watchLatest captured form: F-1/A on 2026-07-30
Not present in the currently captured SEC record. This is not a negative finding.
3 amendments captured for comparison.
Not present in the currently captured SEC record. This is not a negative finding.
Verification queue
- Confirm current legal entity, officers, directors and control from the controlling filing and corporate records.
- Review capitalization, transfer-agent information and any beneficial-ownership questions through the client’s qualified advisers.
- Compare material business, financing and risk disclosure changes in the official source documents.
Source boundary
Forms captured: F-1/A. This is an evidence map, not a safety rating, shell determination, legal opinion, valuation or transaction recommendation. Absence from a captured source is never proof that a fact does not exist.
Open Evidence Snapshot →PUBLIC-RECORD DILIGENCE
Need a documented diligence trail?
Use this issuer dossier as the starting evidence layer. A defined scope can package the official filing history, public company actions and questions for your independently retained advisers to review.
Official filing timeline
- F-1/A · official filing
Biodexa Pharmaceuticals Plc (BDRX)
- F-1/A · official filing
Biodexa Pharmaceuticals Plc (BDRX)
- F-1/A · official filing
Biodexa Pharmaceuticals Plc (BDRX)